BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20045351)

  • 1. Body fat distribution has no effect on serum visfatin levels in healthy female subjects.
    Ersoy C; Sadikoglu G; Orhan H; Guclu M; Sarandol E; Akgun MD; Ozcakir A; Imamoglu S
    Cytokine; 2010 Mar; 49(3):275-8. PubMed ID: 20045351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma visfatin level in women with polycystic ovary syndrome.
    Dıkmen E; Tarkun I; Cantürk Z; Cetınarslan B
    Gynecol Endocrinol; 2011 Jul; 27(7):475-9. PubMed ID: 20586547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
    Ozkaya M; Cakal E; Ustun Y; Engin-Ustun Y
    Fertil Steril; 2010 Feb; 93(3):880-4. PubMed ID: 19111298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats.
    Wang P; Bai C; Xu QY; Xu TY; Su DF; Sassard J; Miao CY
    Clin Exp Pharmacol Physiol; 2010 Sep; 37(9):894-9. PubMed ID: 20456420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients.
    de Luis DA; Gonzalez Sagrado M; Conde R; Aller R; Izaola O; Romero E
    Nutrition; 2008 Jun; 24(6):517-21. PubMed ID: 18343636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children.
    Araki S; Dobashi K; Kubo K; Kawagoe R; Yamamoto Y; Kawada Y; Asayama K; Shirahata A
    Obesity (Silver Spring); 2008 Feb; 16(2):384-8. PubMed ID: 18239648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
    Alghasham AA; Barakat YA
    Saudi Med J; 2008 Feb; 29(2):185-92. PubMed ID: 18246224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating visfatin level is correlated with inflammation, but not with insulin resistance.
    Oki K; Yamane K; Kamei N; Nojima H; Kohno N
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):796-800. PubMed ID: 17634078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of leptin levels in plasma and their reliance on other hormonal factors affecting tissue fat levels in people with various levels of endogenous cotisol].
    Robaczyk MG
    Ann Acad Med Stetin; 2002; 48():283-300. PubMed ID: 14601484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity.
    Malavazos AE; Ermetici F; Cereda E; Coman C; Locati M; Morricone L; Corsi MM; Ambrosi B
    Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):523-30. PubMed ID: 18083357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance.
    Makino S; Handa H; Suzukawa K; Fujiwara M; Nakamura M; Muraoka S; Takasago I; Tanaka Y; Hashimoto K; Sugimoto T
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):12-9. PubMed ID: 16402923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism.
    Martos-Moreno GÁ; Kratzsch J; Körner A; Barrios V; Hawkins F; Kiess W; Argente J
    Int J Obes (Lond); 2011 Oct; 35(10):1355-62. PubMed ID: 21266955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters.
    Caixàs A; Tirado R; Vendrell J; Gallart L; Megía A; Simón I; Llauradó G; González-Clemente JM; Giménez-Palop O
    Clin Endocrinol (Oxf); 2009 Nov; 71(5):733-8. PubMed ID: 19222486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women.
    Chen CC; Li TC; Li CI; Liu CS; Lin WY; Wu MT; Lai MM; Lin CC
    Metabolism; 2007 Sep; 56(9):1216-20. PubMed ID: 17697864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors.
    Sitticharoon C; Nway NC; Chatree S; Churintaraphan M; Boonpuan P; Maikaew P
    Peptides; 2014 Dec; 62():164-75. PubMed ID: 25453978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between circulating visfatin/nicotinamide phosphoribosyltransferase, obesity, inflammation and lipids profile in elderly population, determined by structural equation modeling.
    Owczarek AJ; Olszanecka-Glinianowicz M; Kocełak P; Bożentowicz-Wikarek M; Brzozowska A; Mossakowska M; Puzianowska-Kuźnicka M; Grodzicki T; Więcek A; Chudek J
    Scand J Clin Lab Invest; 2016 Dec; 76(8):632-640. PubMed ID: 27712122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of circulating visfatin concentrations with insulin resistance and low-grade inflammation after dietary energy restriction in Spanish obese non-diabetic women: role of body composition changes.
    Agueda M; Lasa A; Simon E; Ares R; Larrarte E; Labayen I
    Nutr Metab Cardiovasc Dis; 2012 Mar; 22(3):208-14. PubMed ID: 20951014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese women.
    De Pergola G; Ciampolillo A; Paolotti S; Trerotoli P; Giorgino R
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):265-9. PubMed ID: 17547687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum concentration of visfatin in obese women.
    Zahorska-Markiewicz B; Olszanecka-Glinianowicz M; Janowska J; Kocełak P; Semik-Grabarczyk E; Holecki M; Dabrowski P; Skorupa A
    Metabolism; 2007 Aug; 56(8):1131-4. PubMed ID: 17618961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes.
    Bonen A; Tandon NN; Glatz JF; Luiken JJ; Heigenhauser GJ
    Int J Obes (Lond); 2006 Jun; 30(6):877-83. PubMed ID: 16418758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.